Anavex Life Sciences (NASDAQ:AVXL) has completed a Phase 2 clinical trial evaluating Anavex 2-73 (blarcamesine) in patients with Rett syndrome, a rare inherited neurological disorder that occurs primarily in girls that leads to severe impairments. The company plans to release topline results next quarter.
Orally available blarcamesine is a sigma-1 receptor (S1R) agonist. S1Rs play a key role in the modulation of neurotransmission. It is also being investigated for the potential treatment of Parkinson’s disease dementia and mild-to-moderate Alzheimer’s disease.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.